Identification of a new target for neuroprotection after TBI and a new related blood biomarker
|AFFILIATION:||NeurAegis, Pomona, California, United States|
Track: Medical & Biotech
Area: Concussive Injuries
Tech Readiness: TRL 4
Tech Brief: TBI is a major health problem for both military personnel and civilians. We have identified a new target, which plays a causal role in neuronal damage after TBI and an initial molecule to inhibit this target. We have also discovered a new blood biomarker directly related to target activation.
Value Proposition: TBI is a major health problem not only for civilians but also for Veterans and active service members engaged in field operations. The TBI Act of 2008 required several agencies to collaborate for the “development and improvement of TBI diagnostic tool and treatments”. Despite several clinical trials directed at testing the efficacy of potential neurprotective compounds, there are currently no such compounds available. The Blast Injury Research Program was established to develop diagnostic and neuroprotective drugs for TBI. NeurAegis technology is directly related to these goals. On one hand, NeurAegis has identified a blood biomarker, which is directly related to the activation of calpain-2 in the brain as a result of TBI. Further studies are required to establish the predictive value of this biomarker for TBI outcomes and the validation of calpain-2 inhibitors as potential neuroprotective compounds. On the other hand, NeurAegis has identified a selective calpain-2 inhibitor, which has shown remarkable neuroprotective effects when administered shortly after TBI. Recent studies have shown that this molecule can be administered IV with the same neuroprotective effect as when administered ip after TBI. Thus, NeurAegis technology is ideally suited for addressing two major objectives of the DoD in TBI.
Org Type: Early-stage Startup (Seed)
Booth Number: T808